Boron therapy shows promise for tough brain tumors

NCT ID NCT06668987

Completed Disease control Sponsor: Heron Neutron Medical Corp. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed phase I/II trial tested a treatment called boron neutron capture therapy (BNCT) using a boron-based drug (B10 L-BPA) in 10 adults with recurrent meningioma, a type of brain tumor. The goal was to see if the treatment is safe and can shrink tumors or stop them from growing. Participants had already tried other treatments like surgery or radiation. The study measured tumor response using standard imaging criteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: B10 L-BPA (a boron-containing compound)
What this could lead to: If successful, this could offer a new treatment option for recurrent meningioma that has come back after standard therapies.
What could go wrong: This is a very small, early-phase trial (only 10 participants) and results may not apply to all patients. The therapy involves radiation and may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BORON NEUTRON CAPTURE THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BORON NEUTRON CAPTURE THERAPY MENINGIOMA

Contacts and locations

Show contact details

Locations

Taipei Veterans General Hsopital

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.